Boston Scientific’s third quarter saw a positive market reaction, reflecting operational execution across multiple business units. Management attributed the strong results to broad-based growth, especially in electrophysiology and the WATCHMAN left atrial appendage closure device, which CEO Michael Mahoney called “a gem for Boston Scientific.” The company also noted resilient demand in the U.S. and Asia Pacific, with double-digit growth in Japan and China. Mahoney emphasized that growth was driven by elevated procedure volumes and continued adoption of new technologies, while margin performance benefited from favorable product mix, particularly in high-growth areas like electrophysiology and WATCHMAN.
New York, NY – October 23, 2025 – Integer Holdings Corporation (NYSE: ITGR), a leading medical device contract manufacturer, experienced a dramatic downturn in its stock performance today, with shares plummeting a staggering 31.4%. The significant sell-off came despite the company reporting strong third-quarter 2025 earnings that largely met or exceeded
Medical device company Boston Scientific (NYSE:BSX) announced better-than-expected revenue in Q3 CY2025, with sales up 20.3% year on year to $5.07 billion. Guidance for next quarter’s revenue was better than expected at $5.27 billion at the midpoint, 1.7% above analysts’ estimates. Its non-GAAP profit of $0.75 per share was 5.1% above analysts’ consensus estimates.
Risk sentiment deteriorated sharply on Wednesday as a wave of disappointing earnings guidance and escalating U.S.-China trade tensions rattled investor confidence.
Shares of medical device company Boston Scientific (NYSE:BSX)
jumped 4.4% in the morning session after the company reported strong third-quarter results that topped Wall Street's forecasts and raised its full-year financial outlook.
Curious about the top performers within the S&P500 index in the middle of the day on Wednesday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Boston Scientific (NYSE: BSX) has delivered an exceptional third-quarter 2025 earnings report, significantly surpassing analyst expectations and reinforcing its position as a leading innovator in the medical device industry. The strong performance, highlighted by robust sales growth and an upward revision of full-year guidance, has sent a positive signal to
The Death Cross is something you never want to see on a stock you own. Take caution with these three companies that recently were visited by this scary signal.
Medical device company Boston Scientific (NYSE:BSX) reported Q3 CY2025 results beating Wall Street’s revenue expectations, with sales up 20.3% year on year to $5.07 billion. Guidance for next quarter’s revenue was better than expected at $5.27 billion at the midpoint, 1.7% above analysts’ estimates. Its non-GAAP profit of $0.75 per share was 5.1% above analysts’ consensus estimates.
